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More than 22million Americans are estimated to take aspirin daily; 3—5% of patients cov-
ered by health insurance in France received a prescription for antiplatelet drugs in 2006,
representing an estimated 200,000 to 300,000 new patients each year. Aspirin, which
inhibits the formation of platelet thromboxane, is a major treatment to reduce ischaemic
complications in patients with atherothrombotic disease. Clopidogrel, a thienopyridine
derivative, selectively inhibits the platelet adenosine phosphate receptor and is a potent
inhibitor of platelet aggregation. Dipyridamole reduces platelet aggregation by raising
the antiplatelet level of cyclic adenosine monophosphate and cyclic guanosine monophos-
phate, but has non-bleeding side effects. Cilostazol, a phosphodiesterase 3 inhibitor, is
an alternative to aspirin for the prevention of stent restenosis, which works through a
different mechanism.
When clopidogrel is used with aspirin, the antiplatelet effect is synergistic [1]. The clin-
ical beneﬁt of this combination comes mainly from its use in the management of patients
with unstable angina and non-ST or ST-elevation myocardial infarction [2,3] as well as
patients undergoing a percutaneous coronary intervention (PCI) [4]. Clopidogrel added to
aspirin is considered a standard regimen in acute coronary syndromes (ACS) [5,6]. Accord-
ingly, most patients who receive long-term dual antiplatelet therapy have undergone either
stent PCI or had an ACS. However, some patients still experience cardiovascular events in
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pite of treatment with aspirin and/or clopidogrel. This may
e caused by low responsiveness, which has been reported
o range from 1—45% for the two drugs [7]. In particular,
lopidogrel is a prodrug that needs to be metabolized to
he active thiol metabolite by the cytochrome P450 sys-
em. This activation is a source of signiﬁcant inter-individual
ariability in clopidogrel responsiveness.
When considering the long-term or chronic condition of
therothrombosis, it is unclear whether dual antiplatelet
herapy provides superior efﬁcacy over single antiplatelet
herapy. Moreover, the risk/beneﬁt balance could be unac-
eptable because of the increased haemorrhagic risk of
ual antiplatelet therapy. The aim of this review is to
larify chronic atherothrombosis situations in which dual
ntiplatelet therapy can bring additional beneﬁt compared
ith monotherapy. We will not discuss here the beneﬁt
f dual antiplatelet therapy in ACS or in atrial ﬁbrillation
r haemodialysis graft patency, as described recently else-
here [8,9].
Four recent randomized controlled trials—namely the
ATCH, CHARISMA, PROFESS and ESPRIT studies—compared
ual antiplatelet therapy with monotherapy in patient pop-
lations at high risk of atherothrombotic events [10—13].
elected populations were similar, except that patients in
he CHARISMA trial had multiple risk factors. Moreover,
n the ESPRIT and PROFESS studies, diabetes and prior
troke were less prevalent. In these trials, efﬁcacy was
ssessed using a composite endpoint consisting of myocar-
ial infarction, stroke or death from cardiovascular causes,
xcept in the MATCH trial where efﬁcacy was assessed using
hese three same events plus rehospitalization for an acute
schaemic event. In the PROFESS and ESPRIT studies, the
omposite outcome was a secondary endpoint. In all stud-
es, major bleeding was considered as a safety outcome and
as deﬁned as any intracranial bleeding, any fatal bleeding
r any bleeding requiring hospital admission. The results of
hese trials are summarized in Table 1 and Fig. 1.
The MATCH study compared clopidogrel and aspirin with
lopidogrel alone [10]. The combination did not reduce
he incidence of the composite endpoint signiﬁcantly, but
ncreased the risk of major bleeding in 7599 high-risk
atients with recent ischaemic stroke or transient ischaemic
ttack and at least one additional vascular risk factor, fol-
owed over a mean of 18months from randomization.
The CHARISMA study compared clopidogrel and aspirin
ith aspirin alone [11]. There was no signiﬁcant beneﬁt
ssociated with the combination therapy in reducing the
ncidence of the composite endpoint in 15,603 patients with
ither clinically evident cardiovascular disease or multiple
isk factors followed for a median of 28months. However,
here was a suggestion of beneﬁt in patients with symp-
omatic atherothrombosis (including those with documented
yocardial infarction). The rate of major bleeding was
ncreased but the difference was not statistically signiﬁcant.
The PROFESS study compared, over 2.5 years on aver-
ge, aspirin plus dipyridamole with clopidogrel alone in
0,332 patients who had had a stroke [13]. Aspirin plus
ipyridamole did not yield beneﬁt compared with monother-
py, with more major haemorrhagic events among patients
eceiving the combination therapy.
The ESPRIT study compared aspirin plus dipyridamole
ith aspirin alone among 2739 patients with a prior tran-
i
t
d
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ient ischaemic attack or minor stroke of presumed arterial
rigin followed over 3.5 years on average [12]. Aspirin plus
ipyridamole was more effective than aspirin alone in pre-
enting the composite outcome, with a reduction of the risk
f major bleeding.
The comparison of aspirin plus dipyridamole with aspirin
lone has been addressed in previous trials, with similar
opulations. In the ESPS2 [14], there was a marginally sig-
iﬁcant beneﬁt associated with the dual therapy in reducing
he composite outcome of stroke or death (risk reduc-
ion [RR] 0.87, 95% conﬁdence interval [CI], 0.75—1.00),
hile the risk of moderate to severe or fatal bleeding was
on-signiﬁcantly increased (RR 1.13, 95% CI, 0.79—1.63) in
299 patients with recent transient ischaemic accident or
ompleted ischaemic stroke followed for 24months. Two
ther trials before ESPS2 compared aspirin plus dipyridamole
ith aspirin alone [15,16] in patients with recent stroke,
ho were followed up for 36 and 25months, respectively.
hey showed no effect of dual antiplatelet therapy on the
omposite outcomes (stroke or death: RR 0.94, 95% CI,
.57—1.56 [15]; stroke, retinal infarction or death from any
ause: RR 1.00, 95% CI, 0.76—1.31 [16]). Data concerning
ajor bleeding were not reported for these two trials.
The diversity of comparisons and populations precludes
he performance of a formal meta-analysis of these stud-
es in the secondary prevention of cardiovascular events.
SPRIT was the only trial to demonstrate the superiority of
dual antiplatelet therapy (aspirin and dipyridamole) over
spirin alone for both efﬁcacy and safety outcomes. This
as conﬁrmed by two meta-analyses assessing the efﬁcacy
nd safety of the association of aspirin and dipyridamole
ersus aspirin alone in ischaemic stroke: both showed a sig-
iﬁcant beneﬁt of this association in reducing the incidence
f cardiovascular events [12]. On the other hand, there
as no evidence of superiority of aspirin combined with
ipyridamole over clopidogrel in the PROFESS trial. In the
HARISMA trial, a subgroup analysis suggested that in sec-
ndary prevention patients (i.e. with documented history of
stablished vascular disease), the combination reduced the
ncidence of the composite endpoint (hazard ratio [HR] 0.88,
5% CI 0.77—1.00). The rate of major bleeding was not signif-
cantly increased (HR 1.14, 95% CI 0.85—1.52). In the CASPAR
rial, which compared clopidogrel and aspirin with aspirin
lone in 851 patients with peripheral arterial disease and
uccessful venous or prosthetic grafts, dual antiplatelet had
o effect on the incidence of a composite endpoint includ-
ng cardiovascular death, myocardial infarction or stroke (RR
.07, 95% CI 0.65—1.77) with a tendency for an increased
isk of major bleeding (RR 1.80, 95% CI 0.64—5.10) [17]. A
eta-analysis conﬁrmed a 50% excess risk of haemorrhagic
omplications with dual antiplatelet therapy, which should
e considered when choosing the optimal strategy [18]. This
ncrease in risk does not seem clinically important with the
ssociation aspirin—dipyridamole, as conﬁrmed recently in
aemodialysis grafts (RR 0.86, 95% CI 0.55—1.35) [9], but
ndoubtedly the dual association aspirin—clopidogrel carries
n increased risk of major bleeding.
In conclusion, recent large-scale trials have brought lim-
ted evidence of beneﬁt associated with dual antiplatelet
herapy in the long-term secondary prevention of myocar-
ial infarction, stroke or death from cardiovascular causes. A
eneﬁt is observed for the combination of aspirin and dypiri-
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Table 1 Efﬁcacy endpoint: myocardial infarction, stroke or death from cardiovascular causes.
Dual therapy Monotherapy Follow-
up
(months)
Outcome Effect size [95%
conﬁdence
interval]
CHARISMA, 2006 Aspirin + clopidogrel Aspirin 28 MI, stroke or CV
death
0.93 [0.83—1.05]
534/7802 573/7801
ESPRIT, 2006 Aspirin + dipyridamole Aspirin 24 CV death, non-fatal
stroke, non-fatal MI
0.80 [0.66—0.98]
173/1363 216/1376
PROFESS, 2008 Aspirin + dipyridamole Clopidogrel 25 Stroke, retinal infarction, or
death from any cause
0.99 [0.92—1.07]
1333/10181 1333/10,151
MATCH, 2004 Aspirin + clopidogrel Clopidogrel 30 Stroke, MI, CV
death
0.94 [0.84—1.05]
596/3797 636/3802 18 Ischaemic stroke,
MI, CV death, or
rehospitalization
for acute
ischaemia
Safety endpoint: major bleedings
Dual therapy Monotherapy Effect size [95%
conﬁdence interval]
CHARISMA,
2006
Aspirin + clopidogrel Aspirin Fatal bleeding and intracranial haemorrhage, or bleeding that caused
haemodynamic compromise requiring blood or ﬂuid replacement,
inotropic support or surgical intervention
1.25 [0.97—1.61]
130/7802 104/7801
ESPRIT, 2006 Aspirin + dipyridamole Aspirin All intracranial or fatal bleeding, any bleeding requiring hospital
admission
0.67 [0.44—1.03]
35/1363 53/1376
PROFESS, 2008 Aspirin + dipyridamole Clopidogrel Haemorrhagic event that resulted in clinically signiﬁcant disability,
symptomatic intracranial haemorrhage, intraocular bleeding causing loss
of vision, the need for a transfusion of ≥ 2 units of red cells or the
equivalent amount of whole blood, or the need for hospitalization
1.15 [1.00—1.32]
] 419/10181 365/10151
MATCH, 2004 Aspirin + clopidogrel Clopidogrel Any fatal bleeding event; a drop in haemoglobin of 50 g/L; signiﬁcant
hypotension with need for inotropes [haemorrhagic shock]; symptomatic
intracranial haemorrhage, or transfusion of 4 units of red blood cells or
equivalent amount of whole blood
3.34 [2.09—5.34]
73/3797 22/3802
MI: myocardial infarction; CV death: cardiovascular death from all vascular causes.
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tigure 1. Forest plots of trials comparing the efﬁcacy (upper pan
amole compared with aspirin alone, but not clopidogrel
lone, in the prevention of recurrent stroke. The associa-
ion of aspirin and clopidogrel over the single use of either
rug is not sustained by current literature in the long-term
econdary prevention of stroke, peripheral arterial disease
r coronary artery disease, except in this last situation for
he speciﬁc indication due to the presence of a coated
tent. We can thus question on opportunity to continue
o evaluate dual antiplatelet therapy in these indications.
his might leave space for new opportunities that have
merged to address the deﬁciencies in current antiplatelet
C
Tnd safety (lower panel) of dual versus mono antiplatelet therapy.
herapy. Among these are thrombin receptor antagonists
nd P2Y12 receptor antagonists such as prasugrel or can-
relor. These drugs have pharmacological properties that
ranslate into increased potency, more rapid onset of action
nd less variability in response compared with standard
herapy.onﬂict of interest statement
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